Status:
COMPLETED
Heterogeneity in ASD: Biological Mechanisms, Trajectories, and Treatment Response
Lead Sponsor:
University of California, Los Angeles
Conditions:
Children With Autism
Eligibility:
All Genders
12-36 years
Phase:
NA
Brief Summary
Parent-mediated interventions often target social communication in young children with ASD, although to date studies yield inconsistent effects. One reason for the limited evidence may be the consider...
Detailed Description
While social communication is a core developmental deficit that characterizes children with ASD, there is great heterogeneity in both presentation and gains with treatment. Long term outcomes of child...
Eligibility Criteria
Inclusion
- Have elevated scores on the ADOS-2 and clinical concern from a professional (Pediatrician, Psychologist, etc.). For children under the age of 30 months, some of whom may not have a diagnosis of ASD, they must show elevated risk in the mild-to-moderate or moderate-to-severe risk categories on the ADOS-T. For children over the age of 30 months, they must meet clinical cutoff on the ADOS-2, Module 1 or 2.
- Are between 12 months and 36 months
- Have a parent available for parent-mediated sessions 2 times per week in the classroom
Exclusion
- Do not have seizures or are stable on anti-seizure medication
- Do not have associated physical disorders
- Are not co-morbid with other syndromes or diseases unless they come from Project I in our center- 22q11 deletion or TSC children at 12 months with concern for ASD on the ADOS-T.
Key Trial Info
Start Date :
June 15 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 30 2024
Estimated Enrollment :
81 Patients enrolled
Trial Details
Trial ID
NCT03253081
Start Date
June 15 2018
End Date
September 30 2024
Last Update
December 5 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UCLA Semel Institute
Los Angeles, California, United States, 90024